Fig. 9

Preliminary safety evaluation. A Cell viabilities of HT22 cells, HUVECs, RAW cells, and bEnd.3 cells incubated for 24 h with different concentrations of empty formulations. Data are presented as means ± SD (n = 6). B Levels of liver and kidney function markers, including UREA, AST (C), ALT (D), and CREA (E). F Levels of blood cells, including DC and platelets. G Histological examination of major organs derived from mice after treatment (×40 magnification). (**P < 0.01, *P < 0.05, ns, not significant)